Atara Biotherapeutics (ATRA) Accounts Payables (2013 - 2026)

Atara Biotherapeutics has reported Accounts Payables for 14 years, with the latest figure at $637000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 53.97% year-over-year to $637000.0; the trailing twelve-month figure through Mar 2026 stood at $637000.0 (down 53.97% YoY), and the FY2025 full-year result was $127000.0, down 97.09% from the prior year.
• Accounts Payables for Q1 2026 stood at $637000.0, up from $127000.0 in the prior quarter.
• The five-year high for Accounts Payables was $12.8 million in Q2 2022, with the low at $127000.0 in Q4 2025.
• Historically, Accounts Payables has averaged $4.8 million across 5 years, with a median of $4.1 million in 2023.
• Annual changes were most pronounced in 2024 — Accounts Payables climbed 26.95% — and 2025, when it plunged 97.09%.
• Atara Biotherapeutics' Accounts Payables stood at $6.9 million in 2022, then plunged by 46.38% to $3.7 million in 2023, then grew by 18.54% to $4.4 million in 2024, then sank by 97.09% to $127000.0 in 2025, then surged by 401.57% to $637000.0 in 2026.
• The last three Accounts Payables figures came in at $637000.0 (Q1 2026), $127000.0 (Q4 2025), and $318000.0 (Q3 2025), per Business Quant data.